

OncoTherapy Science, Inc.

June 12, 2020

Publication of a scientific paper about exploratory study of
cancer peptide vaccine S-588410

OncoTherapy Science, Inc. (President & CEO: Jae-Hyun Park; hereinafter, “OncoTherapy”) announces that an article reporting results for exploratory study of cancer peptide vaccine S-588410 has been published in *Cancer Immunology, Immunotherapy*.

S-588410 is cancer peptide vaccine licensed out from OncoTherapy to Shionogi & Co., Ltd. It composed of five HLA-A*24:02 restricted peptides derived from five cancer-testis antigens: DEPDC1, MPHOSPH1, URLC10, CDCA1 and KOC1.

This article includes the results of collaborative research between OncoTherapy and Shionogi & Co., Ltd.

In exploratory study, the effect of S-588410 on CD8 positive (+) T-lymphocytes and PD-L1 expression in tumor microenvironment was evaluated. After S-588410 vaccination, peptide-specific CTLs were induced and the densities of functional CD8 (+) cells and PD-L1 cells in esophageal cancer tissue were higher than those before vaccination.

These results suggest that the combination therapy of S-588410 with anti-PD-1 / PD-L1 antibody has the possibility of generating a synergistic effect.

The paper has been published online in *Cancer Immunology, Immunotherapy*.

(<https://link.springer.com/article/10.1007/s00262-020-02619-3>)